LYON, France, Nov. 4, 2009 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the
global leader in therapeutic ultrasound, announced today details relating to its
third quarter 2009 earnings announcement, which will take place on Tuesday,
November 17, 2009, before the opening of the market.
EDAP will hold a conference call on Tuesday, November 17, 2009 at 8:30 a.m. ET
to discuss the results. The dial-in numbers are (877) 407-4134 for domestic
callers and (201) 689-8430 for international. The conference ID number for both
is 337006. A live Webcast of the conference call will be available online from
the investor relations page of the Company's corporate Website at
www.edap-tms.com.
After the live Webcast, the call will remain available on EDAP's Website,
www.edap-tms.com, through December 17, 2009. In addition, a telephonic replay of
the call will be available until November 24, 2009. The replay dial-in numbers
are (877) 660-6853 for domestic callers and (201) 612-7415 for international
callers. Please use account number 356 and event ID number 337006.
About EDAP TMS SA
EDAP TMS SA develops and markets Ablatherm, the most advanced and clinically
proven choice for high-intensity focused ultrasound (HIFU) treatment of
localized prostate cancer. HIFU treatment is shown to be a minimally invasive
and effective treatment option with a low occurrence of side effects.
Ablatherm-HIFU is generally recommended for patients with localized prostate
cancer (stages T1-T2) who are not candidates for surgery or who prefer an
alternative option, or for patients who failed radiotherapy treatment. Approved
in Europe as a treatment for prostate cancer, Ablatherm-HIFU (High Intensity
Focused Ultrasound) is currently undergoing evaluation in a multicenter U.S.
Phase II/III clinical trial under an Investigational Device Exemption granted by
the FDA. The Company also is developing this technology for the potential
treatment of certain other types of tumors. EDAP TMS SA also produces and
commercializes medical equipment for treatment of urinary tract stones using
extra-corporeal shockwave lithotripsy (ESWL). For more information on the
company, please visit http://www.edap-tms.com, http://www.hifu-planet.com and
http://www.pcaresearch.com.
-0-
CONTACT: EDAP TMS SA
Investor Relations / Legal Affairs
Blandine Confort
+33 4 72 15 31 72
bconfort@edap-tms.com
The Ruth Group
Investors:
R.J. Pellegrino
646-536-7009
rpellegrino@theruthgroup.com
Nick Laudico
646-536-7030
nlaudico@theruthgroup.com
